NovAccess Global (XSNX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $6.5M

Market Cap: $6KFounded: 2005HQ: Cleveland, United States

Sector Ranking#44 in AI / Machine Learning #163 in Diagnostics & Precision Medicine

Overview

NovAccess Global Inc. is a biotechnology company with a dual-pronged strategy: developing its lead asset, TLR-AD1, a personalized dendritic cell therapy for glioblastoma, and building a data-centric platform leveraging AI and blockchain for therapeutic discovery. Key achievements include securing Orphan Drug Designation from the FDA for TLR-AD1 and uplisting to the OTCQB Venture Market. The company's mission is to leverage its patented TLR-AD1 platform and AI-driven analytics to create novel, ultra-targeted immunotherapies that enhance a patient's own immune system to fight cancer.

OncologyNeurology

Technology Platform

A dual-platform approach featuring TLR-AD1, a patented personalized dendritic cell immunotherapy activated by a unique TLR adjuvant combination, and an AI/data analytics platform for discovery in cancer and neurology.

Funding History

2

Total raised:$6.5M

Series A$5MUndisclosedMar 15, 2022

Seed$1.5MUndisclosedJun 15, 2021

Opportunities

TLR-AD1 addresses a critical unmet need in glioblastoma with Orphan Drug Designation secured.

The convergence of a personalized cellular therapy with an AI-driven discovery platform offers a long-term strategy for pipeline expansion beyond a single asset.

Risk Factors

Extreme clinical and regulatory risk as the lead asset is pre-IND.

High financial risk as a pre-revenue micro-cap company dependent on dilutive financing.

Unproven and vaguely defined AI/blockchain platform adds speculative risk.

Competitive Landscape

Faces intense competition in GBM from other immunotherapies and novel modalities. Its AI platform enters a crowded field dominated by well-capitalized specialists, making differentiation challenging without concrete validation or partnerships.